The recruitment represents a significant strategic addition to the company as it continues the development of its innovative drug platform within ...
(MENAFN- Cision) The collaboration will commence with AAX Biotech applying its cutting-edge Seqitope™ technology to characterize antibody candidates of Oblique Therapeutics’ pain program targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results